CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 114 enrolled
Drug / intervention
erlotinib [Tarceva] +1 moredrug
Likely dose
erlotinib [Tarceva] 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01196078
NCT01196078Phase 4Completed
CompareCT.gov

A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan

Hoffmann-La Roche·interventional·Posted Sep 8, 2010·Updated Jul 27, 2015

In Brief

A Phase 4 clinical trial evaluating erlotinib [Tarceva] and vinorelbine for Non-Small Cell Lung Cancer. Completed, enrolled 114 participants across 1 site.

Detailed Summary

This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer. Patients will be randomized to receive either Tarceva (150 mg po daily) or vinorelbine (60 mg/m2 on days 1 and 8 of cycle 1 and 80 mg/m2 for the other 21 days cycles). The anticipated time on study treatment is until disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesTaiwan
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 8, 2010
Enrollment StartFeb 1, 2007
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 15.8 years ago

Interventions

erlotinib [Tarceva]drug

150 mg, orally once a day for up to 6 cycles of 21 days each

vinorelbinedrug

60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles